Mon, Jan 26, 2015, 8:59 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

  • isaac_dji isaac_dji Jan 9, 2006 7:43 AM Flag

    5.5 LOG10 HCV Reduction is UNPREDENTED

    The 5.5 log10 REDUCTION in HCV levels, achieved with VX-950 and PEG-IFN, in 14 days, is the BEST BY FAR. Moreover, this was achieved in genotype 1 hepc patients -- the most difficult HCV genotype to treat effectively (and the most common in the US). In addition, in 50% of the patients, the HCV RNA could no longer be detected (below detection limit).


    "VX-950, an investigational oral hepatitis C virus (HCV) protease inhibitor, dosed in combination with pegylated interferon alfa-2a (Pegasys�; peg-IFN), achieved a rapid and dramatic reduction in plasma viral RNA levels in patients with chronic genotype 1 HCV infection. In this Phase Ib study, the combination of VX-950 and peg-IFN produced an initial median reduction in plasma HCV RNA of more than 3 log10 in the first two days, followed by continued decline to a median 5.5 log10 reduction in HCV RNA at day 14, which equates to a 300,000- fold reduction in viral levels. The majority of patients (6 of 8) receiving the combination achieved HCV RNA levels below the limit of quantitation (30 IU/mL, as measured by the Roche TaqMan� assay) at 14 days, with 4 of 8 patients achieving HCV RNA levels below the limit of detection (10 IU/mL, Roche TaqMan�). The antiviral activity of the combination through 14 days was significantly greater than the activity of VX-950 administered as a single agent, and much greater than peg-IFN alone. In addition, VX-950 appeared to be well-tolerated when dosed alone and in combination with peg-IFN in the study. " (see link below)

    Folks, the REAL ERA of VX-950 (and VRTX) has begun.

    It will all be history soon.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
125.12-0.45(-0.36%)Jan 26 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.